TITLE

Stada plans to expand production at Hemofarm

AUTHOR(S)
Interfax
PUB. DATE
May 2012
SOURCE
Russia & CIS Business & Financial Newswire;5/24/2012, p1
SOURCE TYPE
Newswire
DOC. TYPE
Article
ABSTRACT
MOSCOW. May 24 (Interfax) - Stada CIS, which manages the assets of Germany's Stada Ag in Russia, the CIS and the Baltic states, plans to expand production of drugs at LLC Hemofarm-Obninsk in Kaluga region, the Kaluga pharmaceuticals cluster said in a press release.
ACCESSION #
76123036

 

Related Articles

  • Hemofarm sights on Obninsk. Gordon, Michael // European Chemical News;5/10/2004, Vol. 80 Issue 2099, p31 

    Reports on a pharmaceutical packaging and production plant that will be built by Hemofarm in Obninsk, Russia. Details of a loan provided by the European Bank for Reconstruction and Development (EBRD) to Hemofarm; Information on Hemofarm's export in Russia; Estimated loan provided by EBRD to...

  • Hemofarm Sabac DOO.  // SeeNews Research & Profiles (Company Profiles);2013, p6325 

    A profile of Hemofarm Sabac DOO, also known as Hemofarm Sabac LLC, is presented. The company is based in Sabac, Serbia and specializes in the production of pharmaceuticals. Dragan Tosic is the director of the company. Financial information including total assets, liabilities and profit margins...

  • Stada: biosimilars need different marketing strategy.  // PharmaWatch: Biotechnology;Dec2007, Vol. 6 Issue 12, p15 

    The article reflects on the positive opinion of European Medicines Agency (EMEA) on Stada's anemia drug Silapo that marks the second approval of a biosimilar version of Johnson & Johnson's Eprex in the U.S. It relates to Stada's drug which was named differently from its reference product,...

  • Hospira and STADA's Biosimilar Epoetin Retacrit Receives Positive Opinion Recommending EU Approval.  // BioPharm International;Dec2007, Vol. 20 Issue 12, p13 

    The article focuses on the development of a biosimilar Retacrit drug by Hospira Inc. and STADA Arzneimittel AG. Retacrit is a treatment for anemia associated with chronic renal failure and chemotherapy-induced anemia. The Committee for Medicinal Products for Human Use and the European Commission...

  • STADA - STADA acquires UK branded product company Natures Aid.  // Acquisdata Industry SnapShot Germany Pharmaceuticals;11/23/2016, Issue 6401, p4 

    The article reports on the acquisition of Natures Aid, a family-owned Great Britain-based branded product company, by Stada UK Holdings, an established manufacturer of vitamins, minerals, food supplements and herbal products.

  • Hemofarm DOO.  // SeeNews Research & Profiles (Company Profiles);2013, p6322 

    A profile of Hemofarm DOO, also known as Hemofarm Ltd., is presented. The company is based in Banja Luka, Bosnia and Herzegovina and specializes in the production of pharmaceuticals. Aleksandar Veselinovic is the chief executive officer of the company. Other topics discussed include the company...

  • STADA acquiring rights to Aqualor for EUR131 mln. Interfax // Russia & CIS Business & Financial Newswire;10/21/2013, p1 

    MOSCOW. Oct 21 (Interfax) - STADA is strengthening business activities in Russia with the signing of a contract for the purchase of the branded product portfolio Aqualor for the self-medication of sinusitis and sore throat, the German pharmaceuticals company said in a press release.

  • STADA Founds a Subsidiary in Australia -- Business Activities Expected to Commence in the 3rd Qtr of 2012.  // Biomedical Market Newsletter;3/28/2012, Vol. 21, p1 

    The article provides information on the establishment of a subsidiary in Sydney, New South Wales, by STADA Arzneimittel AG under the name STADA Pharmaceuticals Australia Pty Ltd. The company expects that the subsidiary will commence its business activities in the third quarter of 2012. The new...

  • Generic drug price cuts in Germany.  // PharmacoEconomics & Outcomes News;6/17/2006, Issue 505, p10 

    The article reports on the decision of German drug companies, Sandoz, Hexal and Stada to lower the price of its generic drugs. Hexal's reduction in drugs prices are expected to lead potential savings of 60 million euro annually. The drug reductions of Sandoz are estimated to save the region 7...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics